GlassScriptPhysician profile
William L Blanchet
NPI 1659466837
$1,379.98
in general payments reported to CMS, 2019-2025
19 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $136 · 2021: $147 · 2022: $236 · 2023: $121 · 2024: $170 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $488.83 | 2019-2025 | Evenity, Prolia, Prolia |
| Cleerly, INC. | $196.12 | 2023-2025 | Cleerly Labs, Cleerly Ischemia |
| Abbvie INC. | $109.23 | 2021-2022 | |
| Heartflow, INC. | $88.62 | 2024-2025 | |
| United Therapeutics Corporation | $70.76 | 2019-2020 | |
| Novo Nordisk INC | $66.91 | 2023-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $54.85 | 2019-2022 | |
| Therapeuticsmd, INC. | $44.58 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $38.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.03 | 2019 | |
| Pfizer INC. | $30.41 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $27.80 | 2022 | |
| Dexcom, INC. | $22.38 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $21.74 | 2025 | Verquvo |
| Sunovion Pharmaceuticals INC. | $20.83 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.45 | 2019 | |
| Glaxosmithkline, LLC. | $16.74 | 2023 | Arexvy, Shingrix |
| Edwards Lifesciences Corporation | $16.02 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.89 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Blanchet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.